DEF 14A: Black Hawk Acquisition Seeks Shareholder Approval to Extend Business Combination Deadline to December 2026

Black Hawk Acquisition Corporation, a SPAC, is calling an Extraordinary General Meeting on June 20, 2025, to seek shareholder approval for an 18-month extension to its business combination deadline, aiming to complete its merger with Vesicor Therapeutics or find an alternative target.

Summary

• Black Hawk Acquisition Corporation (SPAC) is holding an Extraordinary General Meeting on June 20, 2025, to vote on extending its business combination deadline.
• The current deadline is June 22, 2025, and the company seeks to extend it up to 18 times, each by one month, until December 22, 2026, for a total of up to 33 months after its IPO.
• This extension requires amendments to the company's Second Amended and Restated Memorandum and Articles of Association and its Investment Management Trust Agreement.
• The company has already entered into a definitive business combination agreement with Vesicor Therapeutics, Inc. on April 26, 2025, but needs more time to consummate it.
• Public shareholders have the right to redeem their shares for cash at an anticipated price of approximately $10.63 per share (based on the Trust Account balance of $73,379,601.56 as of June 2, 2025) if they do not wish to extend.
• The cost of each one-month extension will be $0.033 multiplied by the number of outstanding public shares, up to $55,000 per month, to be deposited into the Trust Account by the Sponsor.
• If the extension proposals are not approved, and a business combination is not completed by June 22, 2025, the company will liquidate, redeeming public shares and rendering rights worthless.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company has a target, the need for an extension indicates a delay in the original plan. The document highlights significant risks associated with the extension, including potential delisting and insufficient funds due to redemptions, which could negatively impact shareholder value. However, the option for shareholders to redeem at a slight premium to market price offers some protection.

Positives

• The company has identified a definitive business combination target, Vesicor Therapeutics, Inc., indicating progress towards a merger.
• The proposed extension provides Black Hawk Acquisition Corporation with up to an additional 18 months (until December 22, 2026) to complete its business combination, reducing immediate liquidation pressure.
• Shareholders who do not wish to participate in the extended timeline have the option to redeem their public shares for cash at a price of approximately $10.63 per share, which is slightly above the closing market price of $10.60 as of June 2, 2025.
• The Sponsor is committed to funding the monthly extension payments, demonstrating continued support for the SPAC's efforts to complete a business combination.

Negatives

• The company has not yet completed its initial business combination, necessitating an extension of its deadline.
• There is no assurance that the extension will lead to the successful consummation of the business combination with Vesicor Therapeutics or any other target.
• Significant redemptions by public shareholders could reduce the cash available in the Trust Account, potentially making it difficult to complete a business combination on commercially acceptable terms or at all.
• The company faces the risk of delisting from Nasdaq if redemptions cause it to fall below continued listing requirements (e.g., minimum public shareholders, publicly held shares, or market value of listed securities).
• The company's rights will expire worthless if it liquidates, and initial shareholders (Sponsor, officers, directors) will not receive any monies from the Trust Account for their Founder Shares or Private Shares.
• The company is subject to various regulatory risks, including potential classification as an unregistered investment company, which could force liquidation.

Risks

• There is no assurance that the Extension Amendment will enable the company to complete a business combination by the Extended Date.
• Redemptions by public shareholders could leave the company with insufficient cash to consummate a business combination on commercially acceptable terms, or at all.
• The company's securities may be delisted from Nasdaq if shareholder redemptions cause it to fail continued listing requirements (e.g., maintaining at least 300 public shareholders, 600,000 publicly held shares, or $50 million Market Value of Listed Securities).
• Delisting from Nasdaq could lead to reduced liquidity, potential "penny stock" designation, limited news/analyst coverage, and decreased ability to raise additional financing or complete a business combination.
• Changes in laws or regulations, or their interpretation (e.g., SEC SPAC Rules adopted January 24, 2024), may increase costs and time needed to complete a business combination.
• The company may be deemed an unregistered investment company under the Investment Company Act, which would require burdensome compliance or force liquidation.
• The Committee on Foreign Investment in the U.S. (CFIUS) or other regulatory agencies may modify, delay, or prevent the business combination, especially if the target has a nexus to critical technologies, infrastructure, or sensitive personal data.
• Trading in the company's securities may be prohibited under the Holding Foreign Companies Accountable Act (HFCAA) if the PCAOB determines it cannot inspect or fully investigate the company's auditor, leading to delisting (though current auditor is US-based and inspected).

Future Outlook

The company aims to complete its initial business combination with Vesicor Therapeutics, Inc. or another suitable target by the newly proposed extended deadline of December 22, 2026. If the extension is approved, the company will continue to operate as a reporting company under the Exchange Act, with its securities publicly traded, while it works towards consummating a merger.

Management Comments

• "You are cordially invited to attend Black Hawk Acquisition Corporation's Extraordinary General Meeting of Shareholders (the Extraordinary General Meeting) to be held on June 20, 2025, 12 p.m. Eastern Time." Kent Louis Kaufman, Chairman of the Board of Directors and Chief Executive Officer.
• "Thank you for your continued support of and interest in Black Hawk Acquisition Corporation." Kent Louis Kaufman, Chairman of the Board of Directors and Chief Executive Officer.
• "The purpose of the Extension Amendment Proposal, the Trust Agreement Amendment Proposal and, if necessary, the Adjournment Proposal, is to allow us more time, if necessary, to complete our business combination."
• "Our Board believes that it is advisable and in the best interest of the Company and our shareholders to obtain the Extension in case it becomes necessary to consummate our initial business combination."
• "The Board has determined that it is in the best interests of Black Hawk to seek an extension of the Termination Date and have Black Hawk shareholders approve the Extension Amendment Proposal to allow for additional time to consummate a Business Combination."
• "Given Black Hawk's commitment of time, effort and financial resources to date with respect to identifying a Business Combination target, circumstances warrant providing Public Shareholders with additional time and opportunity to consider a prospective Business Combination."
• "THE BOARD UNANIMOUSLY RECOMMENDS THAT THE COMPANY'S SHAREHOLDERS VOTE FOR THE EXTENSION AMENDMENT PROPOSAL."
• "THE BOARD UNANIMOUSLY RECOMMENDS THAT THE COMPANY'S SHAREHOLDERS VOTE FOR THE ADJOURNMENT PROPOSAL."

Industry Context

This filing is typical for Special Purpose Acquisition Companies (SPACs) that are approaching their initial business combination deadline without having completed a merger. The need for an extension reflects the challenging market conditions for SPACs, including increased regulatory scrutiny (e.g., SEC SPAC Rules) and investor redemptions, which can complicate deal completion. Many SPACs have sought extensions or liquidated in recent periods due to these factors. The mention of a definitive agreement with Vesicor Therapeutics, Inc. suggests the company is actively pursuing a de-SPAC transaction, a common goal for SPACs.

Comparison to Industry Standards

• The proposed extension mechanism, involving monthly payments by the sponsor into the trust account, is a common practice among SPACs seeking to extend their combination period.
• The redemption price of approximately $10.63 per share, slightly above the $10.00 IPO price, is typical for SPACs, reflecting the interest accrued in the trust account.
• The risk factors cited, such as potential delisting due to redemptions, increased regulatory costs (SEC SPAC Rules), and the possibility of being deemed an investment company, are standard challenges faced by SPACs in the current regulatory environment.
• The requirement to maintain net tangible assets above $5,000,001 after redemptions is a common SPAC charter provision to ensure the company remains viable for a business combination.

Corporate Governance

Related Party Transactions

• The Sponsor (Black Hawk Management LLC) will deposit funds into the Trust Account for each one-month extension ($0.033 per public share, up to $55,000 per month) and will receive a non-interest bearing, unsecured promissory note for these amounts.
• The Sponsor, officers, directors, and other initial shareholders waived their rights to participate in any liquidating distribution with respect to their Founder Shares or Private Shares if the company liquidates.

Stakeholder Impact

• Shareholders (Public): Have the option to redeem shares for cash if they do not wish to extend, or remain invested with the potential for a business combination but also face risks of delisting and potential loss of investment if no deal is completed.
• Shareholders (Sponsor/Initial): Bear the cost of extensions by depositing funds into the Trust Account and will not receive liquidation distributions on their Founder Shares or Private Shares if the company liquidates. Their investment is contingent on a successful business combination.
• Creditors: The company is obligated under Cayman Islands law to provide for claims of creditors in the event of liquidation, which may take priority over public shareholder claims.
• Vesicor Therapeutics, Inc.: The proposed target company's merger is contingent on Black Hawk securing this extension, impacting their timeline for becoming a public entity.

Next Steps

• Hold the Extraordinary General Meeting of Shareholders on June 20, 2025, to vote on the extension proposals.
• If approved, file the Extension Amendment with the Cayman Islands Registrar of Companies.
• Continue efforts to consummate the business combination with Vesicor Therapeutics, Inc. or another target by December 22, 2026.
• If a definitive agreement for a business combination is reached, a separate meeting will be held for shareholders to vote on that transaction, with separate redemption rights.
• If the extension is not approved and a business combination is not completed by June 22, 2025, the company will liquidate and dissolve.

Key Dates

Recommendation

Keywords

SPAC, Black Hawk Acquisition Corporation, Vesicor Therapeutics, Business Combination, Extension, Proxy Statement, SEC Filing, Shareholder Meeting, Redemption Rights, Trust Account, Corporate Governance, Risk Factors, Nasdaq Listing, Investment Company Act, CFIUS, HFCAA